Acquisition Details
ChrysCapital, one of India's largest private equity firms, has acquired a controlling 70.68% stake in Novartis India Limited (NIL). This transaction represents ChrysCapital's first majority-controlled investment in the Indian pharmaceutical sector. The acquisition marks the separation of NIL from its previous owner, Swiss multinational Novartis AG.
Management Changes
Dr. Vikas Gupta has been appointed as Managing Director and Chief Executive Officer of the organization. Additionally, three new Independent Directors have joined the board:
- Ramesh Ramadurai (appointed as Chairperson of the NIL board)
- Suchita Sharma
- Shashank Sinha
Strategic Intent
The acquisition aims to build NIL into a leading branded-generics platform for the Indian market. ChrysCapital intends to leverage its sector expertise and extensive network to support NIL's next phase of growth. The company will adopt a new name and corporate identity to celebrate its separation from previous ownership.
Company Background
Novartis India Limited has a legacy spanning several decades with a portfolio of trusted brands including Voveran®, Calcium Sandoz®, and Tegrital®. The company operates across key therapeutic areas including pain management, calcium supplementation, gynaecology, neurosciences, and transplant immunology. NIL is listed on both BSE (500672) and NSE (NOVARTIND) and is headquartered in Mumbai.
Financial Impact
Financial impact not quantified in the disclosure. The transaction involves a change in controlling ownership (70.68% stake) but specific transaction value or consideration details are not disclosed.